DEVELOPMENT AND VALIDATION OF UV- VISIBLE SPECTROPHOTOMETER METHOD FOR ESTIMATION OF RIVASTIGMINE IN HUMAN PLASMA.

  • Department of Pharmaceutical Analysis, RBVRR Womens College of pharmacy, Barkatpura, Hyderabad, Telangana, India.
  • Gland Pharma Pvt Ltd, Gandimaisamma, Hyderabad,Telangana,India.
Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

The main purpose of this study was to develop a simple precise, rapid and accurate uv-visible spectrophotometric method for determination of rivastigmine in spiked human plasma by extracting the Rivastimine from spiked human plasma using methanol after extraction it was scanned between 200-400nm by using uv detector and its absorbance maxima was found to be 270nm.the calibration curve was linear in the range of 6-15ppm .the recovery and assay studies of rivastigmine were within 99 to 102% indicating that the proposed method can be quality control analysis of rivastigmine.

  1. Winblad, B.; Grossberg, G.; Fr?lich, L.; Farlow, M.; Zechner, S.; Nagel, J.; Lane, R. (2007). "IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease".?Neurology.
  2. Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002;2(1):11-25.
  3. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ. 1999 6;318(7184):633-8.
  4. Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. ClinTher. 2004;26(7):980-90.
  5. Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 1998;11(4):211-216.
  6. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, DurifF,Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2509-18.
  7. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009
  8. Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85.
  9. Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4.
  10. Skoog, Douglas A.; Holler, F. James; Crouch, Stanley R. (2007).?Principles of Instrumental Analysis(6th ed.). Belmont, CA: Thomson Brooks/Cole. pp.?169?173.
  11. Misra, Prabhakar; Dubinskii, Mark, eds. (2002).?Ultraviolet Spectroscopy and UV Lasers. New York:?Marcel Dekker.?ISBN978-0-8247-0668-5.
  12. Metha, Akul (14 May 2012).?"Limitations and Deviations of Beer?Lambert Law".?info.
  13. Puluido A, Ruusanches I, Boque R, Rius FX. Uncertainty of results in routine qualitative analysis in analytical chemistry. J Pharm Biomed Anal 2005; 22:647-54
  14. Lang JR, Bolton S. A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry--1. Experimental considerations. J Pharm Biomed Anal 1991;9(5):357-61
  15. Shah VP. The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical method validation. AAPS J 2007;9(1):43-7
  16. Buick AR, Doig MV, Jeal SC, Land GS, McDowall RD. Method validation in the bioanalytical laboratory. J Pharm Biomed Anal 1990;8(8-12):629-37
  17. Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. Pharm Methods 2010;1(1):25-38
 

[K. Bhavyasri, M.Sreshta and D.Rambabu. (2019); DEVELOPMENT AND VALIDATION OF UV- VISIBLE SPECTROPHOTOMETER METHOD FOR ESTIMATION OF RIVASTIGMINE IN HUMAN PLASMA. Int. J. of Adv. Res. 7 (May). 954-959] (ISSN 2320-5407). www.journalijar.com

Dr.K. Bhavyasri
Department of Pharmaceutical Analysis, RBVRR Women’s College of pharmacy, Barkatpura, Hyderabad, India

DOI:

Article DOI: 10.21474/IJAR01/9119      
DOI URL: https://dx.doi.org/10.21474/IJAR01/9119

Download Full Paper

Download PDF No. of Downloads: 110 | No. of Views: 314